You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1536 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria
Sep 2025
Document
Document
Document
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025
Cette page s’adresse aux personnes porteuses d’un type de virus du papillome humain (VPH) pouvant parfois causer un cancer du col de l’utérus. Si...
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Feb 2025

Pages